We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impacts of postoperative adjuvant therapies on the survival of women with high-risk early-stage endometrial cancer.
- Authors
Banghyun Lee; Kyungjin Lee; Minkyung Lee; Tae Kyoung Lee; Sung Ook Hwang
- Abstract
Objective: Survival outcomes according to postoperative adjuvant therapeutic strategy in women with early-stage endometrial cancer is unclear. We investigated the impacts of various postoperative adjuvant therapies on the survival of women with high-risk early-stage endometrial cancer. Methods: Korean Health Insurance Review and Assessment Service data were used. The data of 1,341 women who met the eligibility criteria for high-risk early-stage endometrial cancer were selected. The overall survival (OS) outcome was analyzed according to various postoperative adjuvant therapeutic strategies. Results: Women were meanly followed up for 5.9±4.0 years, and the mean ages of women were 58.2±0.3 years. After adjusting for the co-variables, when compared with primary surgery alone, OSs were not different in adjuvant external beam radiation therapy (EBRT) ± brachytherapy, adjuvant brachytherapy alone, adjuvant chemotherapy, or adjuvant hormone therapy in combination with primary surgery, but OS decreased significantly in adjuvant chemoradiotherapy (hazard ratio [HR]=3.759; 95% confidence interval [CI]=1.602-8.819). In addition, after adjusting for the confounding variables, compared with adjuvant EBRT ± brachytherapy, OSs increased significantly in adjuvant brachytherapy alone (HR=0.33; 95% CI=0.11-0.988) and decreased significantly in adjuvant radiotherapy after chemotherapy (HR=4.621; 95% CI=1.638-13.039), but OSs were not different in adjuvant concurrent chemoradiotherapy or adjuvant chemotherapy after radiotherapy. Conclusion: With the exception of adjuvant brachytherapy alone and adjuvant chemotherapy after radiotherapy, postoperative adjuvant therapies have similar impacts on the survival of women with high-risk early-stage endometrial cancer. Large-scale studies are warranted to confirm our results.
- Subjects
ENDOMETRIAL cancer; RADIOTHERAPY; EXTERNAL beam radiotherapy; CHEMORADIOTHERAPY; ADJUVANT chemotherapy; HORMONE therapy; RADIOISOTOPE brachytherapy
- Publication
Journal of Gynecologic Oncology, 2024, Vol 35, p63
- ISSN
2005-0380
- Publication type
Article
- DOI
10.3802/jgo.2024.35.S2.P89